AZD9550

DRUG6 trials

Sponsors

AstraZeneca

Conditions

Healthy ParticipantsHepatic ImpairmentNon-alcoholic SteatohepatitisObesity or OverweightObesity/OverweightOverweight and Obesity

Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

CompletedNCT05848440

AstraZenecaNon-alcoholic Steatohepatitis

Start: 2023-05-02End: 2023-11-13Updated: 2023-12-11

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

RecruitingNCT06151964

AstraZenecaOverweight and Obesity

Start: 2023-09-29End: 2027-01-29Target: 160Updated: 2026-05-12

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

RecruitingNCT07013643

AstraZenecaHealthy Participants

Start: 2025-06-04End: 2026-12-25Target: 50Updated: 2026-05-11

A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234

RecruitingNCT07546760

AstraZenecaHepatic Impairment

Start: 2026-03-20End: 2027-02-04Target: 28Updated: 2026-05-05

Phase 2

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

Active, not recruitingNCT06862791

AstraZenecaObesity or Overweight

Start: 2025-02-18End: 2026-05-25Updated: 2026-04-28

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

RecruitingNCT07017179

AstraZenecaObesity/Overweight

Start: 2025-05-20End: 2026-08-06Target: 871Updated: 2026-04-20